Literature DB >> 3513751

Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence.

H M Groves, R L Kinlough-Rathbone, J F Mustard.   

Abstract

After removal of the endothelium from normal rabbit aortas or after injury to the neointima, the injured surfaces rapidly become nonreactive to circulating platelets. Experiments were done to determine whether prevention of the initial interaction of platelets with the surfaces would influence the loss of vessel wall reactivity. Inhibition of platelet accumulation on the subendothelium by the infusion of PGI2 (850 ng/kg/min) or the administration of dipyridamole (12.5 mg/kg initially followed by 5 mg/kg/hr) for periods of less than 8 hours inhibited platelet accumulation of platelets on the surfaces when the infusions were stopped. If the animals were treated for 8 hours, platelets did not accumulate on the surface when the drugs were discontinued. Thus, an injured vessel wall can develop a nonthrombogenic surface even when platelet adherence is prevented, although approximately 8 hours are required before the surface loses its ability to interact with platelets.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513751     DOI: 10.1161/01.atv.6.2.189

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  9 in total

1.  Wound healing in the media of the normolipemic rabbit carotid artery injured by air drying or by balloon catheter de-endothelialization.

Authors:  M Richardson; M W Hatton; M R Buchanan; S Moore
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells.

Authors:  S M Schwartz; L Foy; D F Bowen-Pope; R Ross
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

3.  Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery.

Authors:  J Fingerle; R Johnson; A W Clowes; M W Majesky; M A Reidy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 4.  Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

5.  Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen.

Authors:  B S Coller; J L Kutok; L E Scudder; D K Galanakis; S M West; G S Rudomen; K T Springer
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

6.  Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

7.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

8.  Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers.

Authors:  J L Hill-West; S M Chowdhury; M J Slepian; J A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

9.  Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.

Authors:  B R Lucchessi; W E Rote; E M Driscoll; D X Mu
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.